Expression of full-length p53 and its isoform Deltap53 in breast carcinomas in relation to mutation status and clinical parameters
about
Cryptic splice sites and split genes.Wogonin and related natural flavones overcome tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) protein resistance of tumors by down-regulation of c-FLIP protein and up-regulation of TRAIL receptor 2 expression.Mutant p53 protein expression and antioxidant status deficiency in breast cancerAssociation between polymorphisms of XRCC1, p53 and MDR1 genes, the expression of their protein products and prognostic significance in human breast cancer.Negative regulation of p53 by Ras superfamily protein RBEL1AMapping genetic alterations causing chemoresistance in cancer: identifying the roads by tracking the drivers.Expression of p53β and Δ133p53 isoforms in different gastric tissues.Sumoylation of HDAC2 promotes NF-κB-dependent gene expression.Splicing of mouse p53 pre-mRNA does not always follow the "first come, first served" principle and may be influenced by cisplatin treatment and serum starvation.Simian virus 40 activates ATR-Delta p53 signaling to override cell cycle and DNA replication control.The novel p53 isoform "delta p53" is a misfolded protein and does not bind the p21 promoter site.Mutation Analysis of TP53 Tumor Suppressor Gene in Colorectal Cancer in Patients from Iran (Kerman Province).
P2860
Q33864405-7405163A-733A-4FF3-A309-3882F7B8D8D5Q35643815-278464EA-256E-48C5-BAA7-7FBFE116A72BQ35729171-3B2D565D-AF72-445A-8CEB-DDCD1B4FDC19Q36771421-7D9B619F-C92E-450F-B409-11DAB16A6A9CQ36920895-DB0F32D0-5FA3-4548-81C6-40D332FD4E5BQ38087850-87A626C3-0B80-456D-998E-705A0095937AQ38815869-DEBB84CB-4D29-4AC5-8EBD-46E5DBCB94E6Q38907048-0FD1C752-BF3B-4371-B054-0D7747B6241DQ39323969-14CFD4DF-FADB-43A6-8A6C-006EE863AE9BQ39671264-BFD8AE30-FC9A-4A90-8D66-98D9472CE0BAQ39962118-74E2A65A-3197-4373-BBB5-D345212005B4Q43236627-19746957-8CD0-4451-8CA5-0324C8ADF923
P2860
Expression of full-length p53 and its isoform Deltap53 in breast carcinomas in relation to mutation status and clinical parameters
description
2006 nî lūn-bûn
@nan
2006 թուականին հրատարակուած գիտական յօդուած
@hyw
2006 թվականին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Expression of full-length p53 ...... status and clinical parameters
@ast
Expression of full-length p53 ...... status and clinical parameters
@en
Expression of full-length p53 ...... status and clinical parameters
@en-gb
Expression of full-length p53 ...... status and clinical parameters
@nl
type
label
Expression of full-length p53 ...... status and clinical parameters
@ast
Expression of full-length p53 ...... status and clinical parameters
@en
Expression of full-length p53 ...... status and clinical parameters
@en-gb
Expression of full-length p53 ...... status and clinical parameters
@nl
prefLabel
Expression of full-length p53 ...... status and clinical parameters
@ast
Expression of full-length p53 ...... status and clinical parameters
@en
Expression of full-length p53 ...... status and clinical parameters
@en-gb
Expression of full-length p53 ...... status and clinical parameters
@nl
P2093
P2860
P50
P356
P1433
P1476
Expression of full-length p53 ...... status and clinical parameters
@en
P2093
Irene Dornreiter
Simen Myhre
Stephanie B Geisler
P2860
P2888
P356
10.1186/1476-4598-5-47
P407
P50
P577
2006-01-01T00:00:00Z
P5875
P6179
1006801469